Plain-English translation of NCT07018245 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Depression research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase II clinical trial testing a new medication called for depression. Researchers want to find out if this medication is safe and works better than a placebo (a fake pill with no active drug) at treating depressive symptoms. About 150 people will participate, with some receiving the medication at different doses and others receiving placebo.
Depression affects millions of people, and current treatments don't work for everyone. This trial is testing whether this new medication could be another option to help people manage their depression more effectively.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to take either the new medication (at one of two doses) or a placebo pill for 8 weeks. You'll take your assigned pill by mouth every day. During the study, you'll have visits where researchers check how you're doing and how safe the medication is. After the 8 weeks of treatment, you'll have one more follow-up visit about a week later.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Hangzhou PhecdaMed Co., Ltd.
Enrollment target
~150 participants
Started
July 2025
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dong Liu
Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.